vs

Side-by-side financial comparison of PROCEPT BioRobotics Corp (PRCT) and SITIME Corp (SITM). Click either name above to swap in a different company.

SITIME Corp is the larger business by last-quarter revenue ($113.3M vs $83.1M, roughly 1.4× PROCEPT BioRobotics Corp). SITIME Corp runs the higher net margin — 8.1% vs -38.1%, a 46.1% gap on every dollar of revenue. On growth, SITIME Corp posted the faster year-over-year revenue change (66.3% vs 20.2%). Over the past eight quarters, SITIME Corp's revenue compounded faster (85.2% CAGR vs 24.8%).

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

SiTime Corporation is a publicly traded fabless chipmaker based in Santa Clara, California that develops micro-electromechanical systems (MEMS), used for timing devices in electronics.

PRCT vs SITM — Head-to-Head

Bigger by revenue
SITM
SITM
1.4× larger
SITM
$113.3M
$83.1M
PRCT
Growing faster (revenue YoY)
SITM
SITM
+46.1% gap
SITM
66.3%
20.2%
PRCT
Higher net margin
SITM
SITM
46.1% more per $
SITM
8.1%
-38.1%
PRCT
Faster 2-yr revenue CAGR
SITM
SITM
Annualised
SITM
85.2%
24.8%
PRCT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
PRCT
PRCT
SITM
SITM
Revenue
$83.1M
$113.3M
Net Profit
$-31.6M
$9.2M
Gross Margin
64.9%
56.4%
Operating Margin
-4.1%
1.6%
Net Margin
-38.1%
8.1%
Revenue YoY
20.2%
66.3%
Net Profit YoY
-27.9%
148.7%
EPS (diluted)
$-0.56
$0.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRCT
PRCT
SITM
SITM
Q1 26
$83.1M
Q4 25
$76.4M
$113.3M
Q3 25
$83.3M
$83.6M
Q2 25
$79.2M
$69.5M
Q1 25
$69.2M
$60.3M
Q4 24
$68.2M
$68.1M
Q3 24
$58.4M
$57.7M
Q2 24
$53.4M
$43.9M
Net Profit
PRCT
PRCT
SITM
SITM
Q1 26
$-31.6M
Q4 25
$-29.8M
$9.2M
Q3 25
$-21.4M
$-8.0M
Q2 25
$-19.6M
$-20.2M
Q1 25
$-24.7M
$-23.9M
Q4 24
$-18.9M
$-18.8M
Q3 24
$-21.0M
$-19.3M
Q2 24
$-25.6M
$-26.8M
Gross Margin
PRCT
PRCT
SITM
SITM
Q1 26
64.9%
Q4 25
60.6%
56.4%
Q3 25
64.8%
53.5%
Q2 25
65.4%
51.9%
Q1 25
63.9%
50.3%
Q4 24
64.0%
52.6%
Q3 24
63.2%
51.1%
Q2 24
59.0%
49.1%
Operating Margin
PRCT
PRCT
SITM
SITM
Q1 26
-4.1%
Q4 25
-40.6%
1.6%
Q3 25
-27.8%
-19.2%
Q2 25
-28.0%
-35.4%
Q1 25
-39.7%
-46.6%
Q4 24
-28.9%
-33.8%
Q3 24
-38.4%
-43.1%
Q2 24
-50.3%
-73.7%
Net Margin
PRCT
PRCT
SITM
SITM
Q1 26
-38.1%
Q4 25
-39.1%
8.1%
Q3 25
-25.7%
-9.6%
Q2 25
-24.7%
-29.0%
Q1 25
-35.8%
-39.6%
Q4 24
-27.6%
-27.6%
Q3 24
-35.9%
-33.5%
Q2 24
-48.0%
-61.0%
EPS (diluted)
PRCT
PRCT
SITM
SITM
Q1 26
$-0.56
Q4 25
$-0.54
$0.44
Q3 25
$-0.38
$-0.31
Q2 25
$-0.35
$-0.84
Q1 25
$-0.45
$-1.01
Q4 24
$-0.34
$-0.80
Q3 24
$-0.40
$-0.83
Q2 24
$-0.50
$-1.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRCT
PRCT
SITM
SITM
Cash + ST InvestmentsLiquidity on hand
$245.6M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$347.7M
$1.2B
Total Assets
$487.1M
$1.3B
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRCT
PRCT
SITM
SITM
Q1 26
$245.6M
Q4 25
$286.5M
Q3 25
$294.3M
Q2 25
$302.7M
Q1 25
$316.2M
Q4 24
$333.7M
Q3 24
$196.8M
Q2 24
$214.1M
Total Debt
PRCT
PRCT
SITM
SITM
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
PRCT
PRCT
SITM
SITM
Q1 26
$347.7M
Q4 25
$365.9M
$1.2B
Q3 25
$380.3M
$1.1B
Q2 25
$385.8M
$1.1B
Q1 25
$389.2M
$692.5M
Q4 24
$402.2M
$699.7M
Q3 24
$241.2M
$696.2M
Q2 24
$251.8M
$692.5M
Total Assets
PRCT
PRCT
SITM
SITM
Q1 26
$487.1M
Q4 25
$508.1M
$1.3B
Q3 25
$511.5M
$1.3B
Q2 25
$513.1M
$1.3B
Q1 25
$519.4M
$872.1M
Q4 24
$534.0M
$885.0M
Q3 24
$374.1M
$877.9M
Q2 24
$374.4M
$878.6M
Debt / Equity
PRCT
PRCT
SITM
SITM
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRCT
PRCT
SITM
SITM
Operating Cash FlowLast quarter
$25.4M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
11.5%
Capex IntensityCapex / Revenue
10.9%
Cash ConversionOCF / Net Profit
2.77×
TTM Free Cash FlowTrailing 4 quarters
$35.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRCT
PRCT
SITM
SITM
Q1 26
Q4 25
$-10.3M
$25.4M
Q3 25
$-6.6M
$31.4M
Q2 25
$-15.0M
$15.3M
Q1 25
$-17.0M
$15.0M
Q4 24
$-32.4M
$13.5M
Q3 24
$-18.8M
$8.2M
Q2 24
$-15.7M
$-181.0K
Free Cash Flow
PRCT
PRCT
SITM
SITM
Q1 26
Q4 25
$-12.2M
$13.0M
Q3 25
$-9.5M
$26.3M
Q2 25
$-17.8M
$-2.9M
Q1 25
$-18.8M
$-1.3M
Q4 24
$-33.6M
$-2.4M
Q3 24
$-19.0M
$-6.7M
Q2 24
$-16.8M
$-2.7M
FCF Margin
PRCT
PRCT
SITM
SITM
Q1 26
Q4 25
-15.9%
11.5%
Q3 25
-11.4%
31.5%
Q2 25
-22.5%
-4.2%
Q1 25
-27.2%
-2.1%
Q4 24
-49.2%
-3.5%
Q3 24
-32.6%
-11.6%
Q2 24
-31.4%
-6.3%
Capex Intensity
PRCT
PRCT
SITM
SITM
Q1 26
Q4 25
2.4%
10.9%
Q3 25
3.4%
6.1%
Q2 25
3.5%
26.2%
Q1 25
2.7%
27.0%
Q4 24
1.7%
23.3%
Q3 24
0.4%
25.7%
Q2 24
2.0%
5.8%
Cash Conversion
PRCT
PRCT
SITM
SITM
Q1 26
Q4 25
2.77×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

SITM
SITM

Segment breakdown not available.

Related Comparisons